Resolvin D1 (RvD1) is an endogenous chemical mediator derived from omega-3 fatty acids, spontaneously produced by the human body to resolve inflammation and repair damaged tissues. RvD1 is defective in CF: researchers have shown in previous projects (FFC#21/2014 and FFC#19/2016) that its administration could be beneficial to CF patients. In order to advance the molecule’s clinical development, appropriate formulations of RvD1 must be prepared to be tested in preclinical studies. In the current pilot project, innovative formulations of RvD1 will be loaded into small particles (i.e. nanoparticles or sSNP), suitable to be administered either orally, sublingually or by inhalation. The sSNP nanoparticles are intended to improve the stability and effectiveness of RvD1; they will be tested in CF mouse models and also in leukocytes and epithelial cells from CF volunteers. The project will be carried out in collaboration with the CNR laboratories in Lecce and the Emory Children’s Center in Atlanta. The prospect is to obtain the most effective formulation for a new compound with anti-inflammatory and anti-infective effect to be brought to clinical trials.